Fractyl Health, Inc. Common Stock – NASDAQ:GUTS

Add to watchlist

-0.97

-49.24%

Market closed

Open in about 7 hours

-56.99%

month

-56.99%

quarter

Market Cap	86.09M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Fractyl Health, Inc. Common Stock (NASDAQ:GUTS): Profit margin
2020	0	-30.48M
2023	120K	-77.09M	-64242.5%

Fractyl Health, Inc. Common Stock (NASDAQ:GUTS): Earnings per share (EPS)
2024-05-13	-0.3	-0.75

Fractyl Health, Inc. Common Stock (NASDAQ:GUTS): Debt to assets
2023	76212000	401.27M	526.52%

Fractyl Health, Inc. Common Stock (NASDAQ:GUTS): Cash Flow
2023	-42.82M	-359K	27.43M

Fractyl Health, Inc. Common Stock alternative data

Fractyl Health, Inc. Common Stock
Employees

Fractyl Health, Inc. Common Stock (NASDAQ:GUTS): Employee count
Mar 2024	88
Apr 2024	88
May 2024	102
Jun 2024	111
Jul 2024	111
Dec 2024	122

Fractyl Health, Inc. Common Stock
Latest News

Thursday, 12 December 2024
07:00	Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)	globenewswire.com
Monday, 9 December 2024
07:00	Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)	globenewswire.com
Tuesday, 26 November 2024
07:00	Fractyl Health to Participate in the Upcoming December Conferences	globenewswire.com
Thursday, 14 November 2024
23:01	Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript	seekingalpha.com
Tuesday, 12 November 2024
16:05	Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates	globenewswire.com
Monday, 4 November 2024
16:05	Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024	globenewswire.com
Tuesday, 29 October 2024
07:00	Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024	globenewswire.com
Monday, 28 October 2024
07:00	Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024	globenewswire.com
Tuesday, 24 September 2024
07:00	Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference	globenewswire.com
Tuesday, 3 September 2024
07:00	Fractyl Health to Participate in Upcoming September Investor Conferences	globenewswire.com
Wednesday, 14 August 2024
21:27	Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript	seekingalpha.com
16:05	Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates	globenewswire.com
Wednesday, 7 August 2024
07:00	Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024	globenewswire.com
Tuesday, 30 July 2024
07:00	Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs	globenewswire.com
Tuesday, 25 June 2024
07:00	Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day	globenewswire.com
Monday, 24 June 2024
06:00	Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates	globenewswire.com
Sunday, 23 June 2024
13:30	Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions	globenewswire.com
Monday, 20 May 2024
06:00	Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024	globenewswire.com
Monday, 13 May 2024
22:37	Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript	Seeking Alpha
Wednesday, 8 May 2024
06:00	Fractyl Health to Present at BofA Securities 2024 Health Care Conference	GlobeNewsWire
Tuesday, 7 May 2024
06:00	Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024	GlobeNewsWire
Wednesday, 17 April 2024
15:10	The 3 Most Volatile Stocks for Short-Term Traders: April 2024	InvestorPlace
Tuesday, 19 March 2024
08:08	Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)	Benzinga
Sunday, 4 February 2024
06:16	U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings	Seeking Alpha
Friday, 2 February 2024
13:44	Fractyl Health valued at $654.6 mln in tepid debut	Reuters
Thursday, 1 February 2024
21:39	Fractyl Health prices US IPO below range to raise $110 mln	Reuters
Tuesday, 30 January 2024
14:29	GUTS IPO News: 5 Things to Know as Fractyl Health Plans to Go Public	InvestorPlace

Ideas & Opinions

Seeking Alpha 16 Jul 2025

Fractyl Health: Speculative Buy With Binary Risk
Seeking Alpha 4 Feb 2024

U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings

Frequently Asked Questions (FAQ)

What's the price of Fractyl Health, Inc. Common Stock stock today?

One share of Fractyl Health, Inc. Common Stock stock can currently be purchased for approximately $1.
When is Fractyl Health, Inc. Common Stock's next earnings date?

Unfortunately, Fractyl Health, Inc. Common Stock's (GUTS) next earnings date is currently unknown.
Does Fractyl Health, Inc. Common Stock pay dividends?

No, Fractyl Health, Inc. Common Stock does not pay dividends.
How much money does Fractyl Health, Inc. Common Stock make?

Fractyl Health, Inc. Common Stock has a market capitalization of 86.09M. Fractyl Health, Inc. Common Stock made a loss 77.09M US dollars in net income (profit) last year or -$0.75 on an earnings per share basis.
What is Fractyl Health, Inc. Common Stock's stock symbol?

Fractyl Health, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "GUTS".
What is Fractyl Health, Inc. Common Stock's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Fractyl Health, Inc. Common Stock?

Shares of Fractyl Health, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Fractyl Health, Inc. Common Stock have?

As Dec 2024, Fractyl Health, Inc. Common Stock employs 122 workers, which is 10% more then previous month and 20% more then previous quarter.
What is Fractyl Health, Inc. Common Stock's official website?

The official website for Fractyl Health, Inc. Common Stock is fractyl.com.
How can i contact Fractyl Health, Inc. Common Stock?

Fractyl Health, Inc. Common Stock can be reached via phone at +7 819028800.

Fractyl Health, Inc. Common Stock

fractyl.com

Exchange:

NASDAQ

Full time employees:

122

Industry:

Biotechnology

Sector:

Healthcare

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

+7 819028800

17 Hartwell Avenue
Lexington, 02421

:
ISIN: US35168W1036
: